The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial. Those women with the highest expression of the drug’s target, MUC16, gained the most benefit from treatment, which may help researchers predict which patients will benefit from treatment.